Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Dorte Aalund Olsen is active.

Publication


Featured researches published by Dorte Aalund Olsen.


Virchows Archiv | 2010

Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer

Torben Hansen; Flemming Brandt Sørensen; Karen-Lise Garm Spindler; Dorte Aalund Olsen; Rikke Fredslund Andersen; Jan Lindebjerg; Ivan Brandslund; Anders Jakobsen

The measurement of microvessel density (MVD) is a widely accepted method for assessing the neoangiogenetic activity in neoplasia. The aim of the present study was to compare MVD with single nucleotide polymorphisms (SNPs) in the vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2 genes and, furthermore, with quantitative measurements of the receptors in colorectal cancer (CRC) tissue. Prognosis was also assessed. Blood and tissue were collected from 110 patients surgically resected for CRC. SNPs were analysed from genomic DNA by polymerase chain reaction. MVD was assessed by immunohistochemistry using CD34 and CD105 combined with caldesmon in order to identify also immature vessels. Microvessels were counted in three fields of vision, and the mean MVD was used for statistical analysis. The VEGFR-2 1192 C/T and −604 T/C SNPs were associated with the MVD assessed by CD105. The median MVD score for the 1192 CC genotype was significantly lower compared to the CT + TT genotypes (p = 0.002). The median MVD score for the −604 CC genotype was significantly higher compared to the TT + TC genotypes (p = 0.009). A possible association, although non-significant, was demonstrated for the CD34-positive microvessels. The 1192 CC genotype and the −604 TT + TC genotypes correlated with improved survival. This is the first report on correlations between SNPs in the VEGF receptor genes and MVD in patients with CRC. Associations were shown between two SNPs in the VEGFR-2 gene and the CD105-positive microvessels indicating an impact on neoangiogenesis. Moreover, an association between the SNPs and survival was demonstrated. The clinical implications of these findings need further investigations.


Clinical Cancer Research | 2008

Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors.

Karina Dahl Steffensen; Marianne Waldstrøm; Dorte Aalund Olsen; Thomas Corydon; Karen Axelgaard Lorentzen; Hans Jørgen Knudsen; Ulla Jeppesen; Ivan Brandslund; Anders Jakobsen

Purpose: Dysfunction of the epidermal growth factor (EGF) complex is essential to the growth and development of many human tumors. Overexpression of the EGF receptor (EGFR) is a characteristic finding in a considerable number of solid tumors and often signalizes poor prognosis. There is a major disagreement among researchers about both the frequency and possible clinical importance of EGFR overexpression in ovarian cancer. The type III variant of EGFR (EGFRvIII) is a mutant with a deletion. Contrary to the wild-type, it is constitutively active. EGFRvIII has not been found in normal tissue, and consequently, it is an attractive tumor-specific candidate for molecular targeted treatment. The literature dealing with this mutation in ovarian cancer has been very sparse. Experimental Design: Tissue from 225 patients who underwent surgery for a pelvic mass was collected consecutively. The samples included 99 ovarian/peritoneal/tuba cancers, 17 ovarian borderline tumors, 66 benign ovarian tumors, 15 other cancer types, 24 normal ovarian biopsies, and 4 miscellaneous. The presence of EGFRvIII was investigated both by PCR analyses for EGFRvIII gene expression and with protein analysis by Western blots. Results: None of the tissue samples was positive for the EGFRvIII mutation neither at the mRNA level nor at the protein level. Conclusions: The EGFRvIII mutation seems to be very rare in ovarian tissue. Our data indicate that EGFRvIII is not a part of the malignant phenotype in ovarian cancer and should not be pursued as a therapeutic target for treatment of this disease.


Journal of Cancer Research and Clinical Oncology | 2010

The importance of ¡460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer

Torben Hansen; Karen-Lise Garm Spindler; Karen Axelgaard Lorentzen; Dorte Aalund Olsen; Rikke Fredslund Andersen; Jan Lindebjerg; Ivan Brandslund; Anders Jakobsen

PurposeThe present study investigated the functional influence of the single nucleotide polymorphisms (SNPs) −460 C/T and +405 G/C at vascular endothelial growth factor A (VEGF-A), mRNA and protein levels in colorectal cancer (CRC) and normal colorectal tissue.MethodsBlood and tissue were collected from 113 patients surgically resected for colorectal cancer. SNPs were analysed from genomic DNA by PCR, the VEGF-A gene expression analysis was performed by RT–PCR and protein analysis by ELISA.ResultsThe T-allele in the −460 C/T SNP and the C-allele in the +405 G/C SNP were associated with significantly lower VEGF-A protein levels in normal colorectal tissue. There were no differences in protein levels in the malignant tissue according to genotypes. No differences were observed at the gene expression levels either.ConclusionThe results indicate that the two SNPs have a functional influence on the VEGF-A protein levels in normal colorectal tissue. The possible clinical implications of the findings need further investigation.


Clinical Chemistry and Laboratory Medicine | 2009

Serum HER-2 concentrations for monitoring women with breast cancer in a routine oncology setting

Erik Hugger Jakobsen; Sven Tyge Langkjer; Susanne Bokmand; Birthe Østergaard; Dorte Aalund Olsen; Jonna Skov Madsen; Ivan Brandslund

Abstract Background: The purpose of this study was to determine the positive predictive value (PPV) of positive serum human epidermal growth factor receptor-2 (HER-2) for monitoring women with breast cancer following diagnosis and treatment in a routine clinical setting. Methods: Serum HER-2 was measured in 1348 patients with breast cancer: 837 during routine oncology clinic visits and 511 following new diagnosis. All patients with positive serum HER-2, 1/5 of negative patients from the oncology clinic, and all the newly diagnosed were followed; a total of 862 patients. Serum HER-2 was measured using the Bayer ADVIA Centaur assay. Tissue HER-2 was determined using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). IHC +3 or IHC +2 and FISH>2.0 were positive. Patients were considered to have positive serum HER-2 when at least two values were >15 ng/mL. Recurrence, progression and regression were diagnosed according to usual clinical practice. Serum HER-2 concentrations did not contribute to diagnostic decision-making or selection of treatment. Results: From January 2004 to January 2009, 149 patients were found to have positive serum HER-2. Of these, 35 were tissue HER-2 positive at surgery, 69 tissue-negative and 45 were not determined. Fifty-five of 149 that were serum HER-2 positive (37%, 95% CI: 29–45) had metastases. Among the 35 tissue-positive patients, 25 had recurrence in the form of metastases and there was good correlation between recurrence/progression and increase in serum HER-2 (p<0.0003). There was also a high correlation between effect of treatment and decline in serum HER-2 (p<0.0003). Of the 69 tissue-negative patients, 29 had recurrence in the form of metastases, and there was good correlation with serum HER-2 levels (p<0.000004). In this routine application of serum HER-2, the PPV for metastases recurrence detection in both tissue-positive and tissue-negative was 54 of 104 (52%, 95% CI: 42%–62%), in tissue-positive 25 of 35 (71%, 95% CI: 54%–85%), in tissue-negative 29 of 69 (42%, 95% CI: 30%–54%). The lead time of increases in serum HER-2 before recurrence could be determined in ten tissue-positive patients was 3–24 months (mean 11.3 months), when compared to standard clinical imaging methods. Conclusions: Serum HER-2 is a useful marker for the detection of recurrence of breast cancer and for monitoring the effect of treatment, especially in tissue HER-2 positive patients. Clin Chem Lab Med 2009;47:1117–23.


Journal of Ovarian Research | 2012

Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab.

Christine Vestergaard Madsen; Karina Dahl Steffensen; Dorte Aalund Olsen; Marianne Waldstrøm; Maja Smerdel; Parvin Adimi; Ivan Brandslund; Anders Jakobsen

IntroductionAnti-VEGF treatment has proven effective in recurrent ovarian cancer. However, the identification of the patients most likely to respond is still pending. It is well known that the angiogenesis is regulated by several other pro-angiogenic proteins, e.g. the platelet - derived growth factor (PDGF) system and the fibroblast growth factor (FGF) system. These other signaling pathways may remain active or become upregulated during anti-VEGF treatment.The aim of the present study was to investigate if potential changes of PDGF-BB, PDGF-AA, and FGF2 before and during bevacizumab treatment had predictive value for early progression or survival. Furthermore, we wanted to investigate the importance of serum VEGF in the same cohort.MethodsThis study included 106 patients with chemotherapy-resistant epithelial ovarian cancer who were treated with single agent bevacizumab as part of a biomarker protocol. Patients were evaluated for response by the Response Evaluation Criteria In Solid Tumors (RECIST) and/ or Gynecologic Cancer Intergroup (GCIG) CA125 criteria. Serum samples were collected at baseline and prior to each treatment. FGF2, PDGF-BB, PDGF-AA were quantified simultaneously using the Luminex system, and VEGF-A was measured by ELISA. Eighty-eight baseline samples were avaliable for FGF2, PDGF-BB, PDGF-AA analysis, and 93 baseline samples for VEGF.ResultsHigh baseline serum VEGF was related to poor overall survival. Furthermore, high serum PDGF-BB and FGF2 was of prognostic significance. None of the markers showed predictive value, neither at baseline level nor during the treatment.


Clinical Chemistry and Laboratory Medicine | 2007

HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive.

Dorte Aalund Olsen; Birthe Østergaard; Susanne Bokmand; Peter Wamberg; Erik Jakobsen; Ivan Brandslund

Abstract Background: The level of HER-2/neu in breast cancer cells is normally measured by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH). It determines whether patients should be treated with trastuzumab (Herceptin®). In this study, HER-2 protein in breast cancer tissue was measured using a quantitative method. Methods: Tissue samples of malignant and adjacent benign breast tissue were collected from 118 consecutive women admitted for surgical treatment of breast cancer. The HER-2 protein concentration was determined by 2 HER-2 assays: ELISA and the Bayer ADVIA Centaur assay. Paraffin-embedded tissue sections of the corresponding tumors were analyzed by IHC and FISH. Results: Increased HER-2 concentrations in cancer tissue were found compared to autologous reference tissue (p<0.0001, Wilcoxon test) and normal breast tissue (p<0.0001, Mann-Whitney test). Good concordance rates were observed between the methods: 95.8% for IHC and FISH; 86.4% for IHC and ELISA; and 87.3% for FISH and ELISA. The HER-2 positivity rate was determined to 26.3% by ELISA, 12.7% by IHC and 16.9% by FISH. No correlation was found with tumor grade, axillary node status or serum HER-2 levels. Conclusions: Detection of HER-2 overexpression by measuring HER-2 in tissue extracts by ELISA seems to be more sensitive than IHC and FISH. This suggests that some patients deprived of Herceptin treatment may benefit from this treatment and may also explain the conversion phenomenon from HER-2-negative to HER-2-positive observed in relapse and metastatic disease. Clin Chem Lab Med 2007;45:177–82.


Clinical Chemistry and Laboratory Medicine | 2012

Increased concentrations of growth factors and activation of the EGFR system in breast cancer.

Dorte Aalund Olsen; Troels Bechmann; Birthe Østergaard; Peter Wamberg; Erik Jakobsen; Ivan Brandslund

Abstract Background: In this study the total and phosphorylated amount of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) were measured together with EGFR ligands in tissue samples of breast cancer patients in order to investigate interrelations and possible prognostic values. Methods: Samples of malignant and non-cancer autologous reference tissue were collected from 415 breast cancer patients. The tissue samples were cut and either paraffin-embedded or homogenized in a lysis buffer to extract the proteins. HER2 was measured using both immunohistochemistry (IHC)/fluorescence in situ hybridization (FISH) and ADVIA Centaur. Phosphorylated HER2 and EGFR (pHER2, pEGFR), total EGFR and the ligands: epidermal growth factor (EGF), transforming growth factor-α (TGFα), amphiregulin (AREG), heparin-binding EGF-like growth factor (HB-EGF), betacellulin (BTC) and epiregulin (EREG) were measured using the Luminex. Results: The HER2 positivity rate was determined to be 25.2% by the Centaur method vs. 15.8% by IHC and FISH. HER2, HB-EGF, TGFα and AREG were upregulated in cancer tissue as compared with autologous reference tissue while EGFR, pEGFR and EGF were downregulated (p<10–6). pEGFR in autologous reference tissue was negatively correlated to the number of positive lymph nodes and to the tumor size (p=0.0007 and p=0.001, respectively) and furthermore, decreased in the group of mastectomy operated patients as compared with the lumpectomy group (p<10–6). HB-EGF in cancer tissue was positively associated with high grade tumors (p<10–6) and pHER2, HB-EGF and BTC were associated with poor disease free survival (p=0.017, p=0.012 and p=0.0026, respectively). Conclusions: Our study demonstrated a profound activation of the EGFR system. HB-EGF was increased by factor 10 in cancer tissue and related to the biological aggressiveness of the tumors, and pHER2, HB-EGF and BTC were associated with poor clinical outcome.


Scandinavian Journal of Clinical & Laboratory Investigation | 2013

Evaluation of OneTouch Verio®, a new blood glucose self-monitoring system for patients with diabetes

Karin Littmann; Eva Rabing Brix Petersen; Christel Pussinen; Kristin Danielson; Snezana Djurisic; Heidi Eilertsen; Lamya Garabet; Eva Greibe; Trine Lauritzen; Dorte Aalund Olsen; Suher Othman; Irina Palimaru; Johanna Westerlund

Abstract Introduction. Self-monitoring of blood glucose (SMBG) is important in diabetes management. Reliable and user-friendly instruments are essential. OneTouch Verio® is a new blood glucose concentration-measuring system designed to be used by patients with diabetes and healthcare professionals. The objective of the present study was to evaluate the analytical performance of the OneTouch Verio®. Method. The OneTouch Verio® was evaluated by the Scandinavian evaluation of laboratory equipment for primary healthcare (SKUP) according to a protocol based on ISO 15197 and the American Diabetes Association (ADA) quality goals. Blood samples were collected and measured on the OneTouch Verio® by laboratory personnel and patients with diabetes (n = 91, randomized into groups receiving personal training or mail instructions for the OneTouch Verio® system). Results were compared to a validated routine method, imprecision and bias were calculated. User-friendliness was evaluated with a questionnaire. Results. Quality specifications for blood glucose concentration monitoring systems according to ISO 15197 were fulfilled. The mean coefficients of variation (CV%) of repeatability was 3.4% when tested by laboratory personnel and within the goal of imprecision suggested by ADA. Mean CV% of repeatability for patient self-monitoring was 5.0% and 5.1% in the training- and the mail group, respectively. Total error was 6.4–10.0%. The OneTouch Verio® showed no hematocrit interference or variation between strip lots. Conclusion. The OneTouch Verio® displayed sufficient analytical quality and satisfactory user-friendliness. It is suitable for point-of-care testing of blood glucose concentration when handled by patients and healthcare professionals.


Applied Immunohistochemistry & Molecular Morphology | 2013

The influence of tissue ischemia on biomarker expression in colorectal cancer.

Birgitte Mayland Havelund; Dorte Aalund Olsen; Rikke Fredslund Andersen; Karen-Lise Garm Spindler; Ivan Brandslund; Anders Jakobsen; Flemming Brandt Soerensen

The aim of the present study was to investigate the influence of fixation delay and the perioperative ischemia on hypoxia inducible factor (HIF)-1&agr; gene expression, HIF-1&agr; protein expression, and immunohistochemical (IHC) expression of HIF-1&agr;, GLUT-1, Bcl-2, and Ki-67 in colorectal cancer. The study included 25 surgically removed colorectal tumors. Three sets of samples were collected readily after removal and exposed to 0, 30, and 60 minutes of delay of fixation or freezing. The perioperative ischemia time was registered. In each set of the samples, HIF-1&agr; gene expression was analyzed by quantitative real time polymerase chain reaction, protein concentration of HIF-1&agr; was assessed by enzyme-linked immunosorbent assay, and IHC staining of HIF-1&agr;, GLUT-1, Bcl-2, and Ki-67 was performed. Preoperative formalin-fixed paraffin-embedded biopsies and whole sections of the entire tumor were analyzed by IHC. We found that the HIF-1&agr; gene expression, HIF-1&agr; protein concentration, and IHC expression of HIF-1&agr;, GLUT-1, Ki-67, and Bcl-2 were not systematically affected by either the fixation or freezing delay of the tissue, the perioperative ischemia time, or the total ischemia time (perioperative ischemia+delay of fixation or freezing) in colorectal tumors. However, the intraindividual variation was quite large, which may question the use of individually, non-standardized–handled single biopsies or small tissue samples for analysis of often rather heterogenously expressed biomarkers.


Molecular Medicine Reports | 2009

Quantitative analysis of vascular endothelial growth factor receptors 1 and 2 in colorectal cancer.

Torben Hansen; Karen-Lise Garm Spindler; Karen Axelgaard Lorentzen; Dorte Aalund Olsen; Rikke Fredslund Andersen; Jan Lindebjerg; Ivan Brandslund; Anders Jakobsen

Vascular endothelial growth factor A (VEGF-A) is a key regulator of angiogenesis that binds to the receptors VEGFR-1 and VEGFR-2. It is well known that VEGF-A levels are increased in colorectal cancer (CRC) tissue compared to normal colorectal tissue, but little is known regarding the expression of the VEGFR-1 and -2 receptors. The aim of the present study was to perform a quantitative analysis of VEGFR-1 and -2 at the mRNA and protein level in tumour and normal colorectal tissue from CRC patients. Tissues were collected from 110 patients who underwent surgical resection for CRC. Receptor status was analysed at the gene expression level by real time RT-PCR using β-2-microglobulin and β-actin as reference genes. Protein analysis was performed using the ELISA technique. Gene expression and protein concentrations of VEGFR-1 and -2 were significantly increased in CRC tissue compared to normal colorectal tissue (P<10-6 for both receptors). An association between the gene expression of VEGFR-2 in CRC tissue and disease stage was detected (P=0.055). Significant correlations were also found between the gene expression of VEGFR-1 and -2 in CRC tissue and normal colorectal tissue (P<10-4). The gene expression and protein concentrations of VEGFR-1 and -2 were increased in CRC tissue compared to normal colorectal tissue, indicating that both receptors are important in CRC. The clinical implications of these findings require further investigation.

Collaboration


Dive into the Dorte Aalund Olsen's collaboration.

Top Co-Authors

Avatar

Ivan Brandslund

University of Southern Denmark

View shared research outputs
Top Co-Authors

Avatar

Anders Jakobsen

University of Southern Denmark

View shared research outputs
Top Co-Authors

Avatar

Karina Dahl Steffensen

University of Southern Denmark

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Erik Jakobsen

Odense University Hospital

View shared research outputs
Top Co-Authors

Avatar

Marianne Waldstrøm

University of Southern Denmark

View shared research outputs
Top Co-Authors

Avatar

Torben Hansen

University of Copenhagen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jan Lindebjerg

University of Southern Denmark

View shared research outputs
Top Co-Authors

Avatar

Jonna Skov Madsen

University of Southern Denmark

View shared research outputs
Researchain Logo
Decentralizing Knowledge